SCHEMBL2592259

SCHEMBL2592259

Cc1cc(C)c(CNC(=O)c2cc(-c3ccc(F)cc3)cc3c2cnn3C2CCCC2)c(=O)[nH]1

nearest known ligand 0.67

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
EZH2 Q15910 16/20 0.67
EZH1 Q92800 3/20 0.59
EED O75530 2/20 0.55
RBBP4 Q09028 2/20 0.55
SUZ12 Q15022 2/20 0.55
RBBP7 Q16576 2/20 0.55
AEBP2 Q6ZN18 1/20 0.55
HDAC1 Q13547 2/20 0.54
HDAC6 Q9UBN7 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12498496 0.91 EZH2 (0.66) EZH2EZH1EEDRBBP4SUZ12
SCHEMBL12499131 0.90 EZH2 (0.65) EZH2EZH1EEDRBBP4SUZ12
SCHEMBL12498425 0.90 EZH2 (0.65) EZH2EZH1EEDRBBP4SUZ12
SCHEMBL30388264 0.90 EZH2 (0.65) EZH2EZH1EEDRBBP4SUZ12
SCHEMBL12180885 0.89 EZH2 (0.66) EZH2EZH1EEDRBBP4SUZ12
SCHEMBL2593249 0.89 EZH2 (0.66) EZH2EZH1EEDSUZ12
SCHEMBL12180805 0.88 EZH2 (0.67) EZH2EZH1EEDRBBP4SUZ12
SCHEMBL19391445 0.88 EZH2 (0.69) EZH2EZH1HDAC6
SCHEMBL14716518 0.88 EZH2 (0.65) EZH2EZH1EEDRBBP4SUZ12
SCHEMBL2591592 0.88 EZH2 (0.70) EZH2EZH1EEDRBBP4SUZ12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9018382-B2 Indazoles GLAXOSMITHKLINE LLC (US) 2015-04-28 US claimed
EP-2566328-B1 INDAZOLES GLAXOSMITHKLINE LLC (US) 2015-03-04 EP claimed
US-20140350013-A1 INDAZOLES GLAXOSMITHKLINE LLC 2014-11-27 US claimed
EP-2566328-A1 INDAZOLES GlaxoSmithKline LLC (US) 2013-03-13 EP claimed
US-20130053383-A1 INDAZOLES GLAXOSMITHKLINE LLC 2013-02-28 US claimed
WO-2011140325-A1 INDAZOLES GLAXOSMITHKLINE LLC (US) 2011-11-10 WO claimed
US-9018382-B2 Indazoles GLAXOSMITHKLINE LLC (US) 2015-04-28 US disclosed
US-9018382-B2 Indazoles GLAXOSMITHKLINE LLC (US) 2015-04-28 US disclosed
US-9018382-B2 Indazoles GLAXOSMITHKLINE LLC (US) 2015-04-28 US disclosed
EP-2566328-B1 INDAZOLES GLAXOSMITHKLINE LLC (US) 2015-03-04 EP disclosed
EP-2566328-B1 INDAZOLES GLAXOSMITHKLINE LLC (US) 2015-03-04 EP disclosed
US-20140350013-A1 INDAZOLES GLAXOSMITHKLINE LLC 2014-11-27 US disclosed
US-20140350013-A1 INDAZOLES GLAXOSMITHKLINE LLC 2014-11-27 US disclosed
WO-2013067300-A1 METHOD OF TREATMENT GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2013-05-10 WO disclosed
EP-2566328-A1 INDAZOLES GlaxoSmithKline LLC (US) 2013-03-13 EP disclosed
US-20130053383-A1 INDAZOLES GLAXOSMITHKLINE LLC 2013-02-28 US disclosed
US-20130053383-A1 INDAZOLES GLAXOSMITHKLINE LLC 2013-02-28 US disclosed
US-20130053383-A1 INDAZOLES GLAXOSMITHKLINE LLC 2013-02-28 US disclosed
WO-2011140325-A1 INDAZOLES GLAXOSMITHKLINE LLC (US) 2011-11-10 WO disclosed
WO-2011140325-A1 INDAZOLES GLAXOSMITHKLINE LLC (US) 2011-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053383-A1 INDAZOLES IDH3A, CYP3A7, IDH3B EZH2 1599/4885EZH1 1398/4885EED 3742/4885
US-20140350013-A1 INDAZOLES IDH3A, CYP3A7, IDH3B EZH2 1599/4885EZH1 1398/4885EED 3742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.